Director · Candel Therapeutics, Inc. · Candel Therapeutics, Inc. — Stock Option (Right to Buy)
Side
A
Value
—
Shares
32.0K
Price
—
Executed
Jun 23, 2026
Disclosed
Jun 24, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Jun 23 executedJun 24, 2026 disclosed
CADL · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Candel Therapeutics, Inc. — Stock Option (Right to Buy)
Ticker
CADL
Shares
32.0K
Price per share
$0
Execution date (reported)
Jun 23, 2026
Owned after transaction
32.0K shares
Days from execution to publication
1
What this establishes
Gaeta Renee filed this Form 4 reporting a grant or award of CADL on Jun 23, 2026. It became public on Jun 24, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Gaeta Reneecik:0001742428
Issuer
Candel Therapeutics, Inc.cik:0001841387
Revision history · 0
No field has changed since this record was first ingested.
